- Report
- March 2025
- 200 Pages
Global
From €4195EUR$4,490USD£3,549GBP
- Report
- May 2024
- 133 Pages
Global
From €6071EUR$6,499USD£5,136GBP
- Drug Pipelines
- August 2024
- 150 Pages
Global
From €2606EUR$2,789USD£2,204GBP
- Report
- August 2022
- 161 Pages
Global
From €7007EUR$7,500USD£5,927GBP
- Report
- February 2024
- 118 Pages
Global
From €4438EUR$4,750USD£3,754GBP
- Report
- January 2024
- 156 Pages
United States
€3550EUR$3,800USD£3,003GBP
- Report
- January 2024
- 114 Pages
United States
€3270EUR$3,500USD£2,766GBP
- Report
- February 2024
- 84 Pages
Global
From €3500EUR$4,013USD£3,065GBP
Fluticasone Propionate is a corticosteroid used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It is used to reduce inflammation in the airways, which helps to reduce symptoms such as wheezing, coughing, and shortness of breath. It is available in both inhaler and nasal spray forms, and is often prescribed in combination with other medications. Fluticasone Propionate is a widely used medication in the respiratory drug market, and is often prescribed as a first-line treatment for asthma and COPD.
The Fluticasone Propionate market is highly competitive, with many pharmaceutical companies offering their own branded versions of the drug. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and Sanofi. Other companies such as Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals also offer generic versions of the drug. Show Less Read more